Pharma BD Deal Intelligence
A $11.6B acquisition that gave Sanofi entry into hemophilia treatment through Bioverativ's pipeline. The deal expanded Sanofi's rare disease footprint, though mid-pack critic and outcome scores suggest the returns were unremarkable rather than transformative.
Sanofi acquired Bioverativ for $11.6B for hemophilia treatment.
Sanofi announced the successful completion of its acquisition of Bioverativ Inc. for $105 per share in cash, strengthening its position in the hemophilia…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sanofi acquired Bioverativ for $11.6B for hemophilia treatment.
400 US cases/yr · $12.0B Global hemophilia therapeutics
Hemophilia A is an X-linked bleeding disorder due to Factor VIII deficiency. Treatment has evolved from plasma-derived factors to recombinant and extended half-life products, bispecific antibodies, and gene therapy.
Prophylaxis: emicizumab (Hemlibra, bispecific), EHL Factor VIII. Gene therapy: valoctocogene roxaparvovec (Roctavian). Key players: Roche (Hemlibra $4B+), Sanofi/Sobi (Eloctate/Alprolix from Bioverativ), BioMarin (Roctavian), Takeda (Adynovate).
100 US cases/yr · $3.0B Global hemophilia B therapeutics
Hemophilia B is an X-linked bleeding disorder due to Factor IX deficiency. Gene therapy (Hemgenix/etranacogene dezaparvovec) was the first approved gene therapy for hemophilia B.
Prophylaxis: EHL Factor IX (Alprolix, Idelvion, Rebinyn). Gene therapy: Hemgenix (CSL/uniQure). Key players: Sanofi/Sobi (Alprolix from Bioverativ), CSL Behring (Hemgenix, Idelvion), Novo Nordisk (Rebinyn).
Sanofi SA completed its acquisition of Bioverativ Inc. for $11.6B. Sanofi acquired Bioverativ for $11.6B for hemophilia treatment.
Roche Hemlibra eroded hemophilia A market, forcing ~$2B writedown. Reflects financial performance following Sanofi SA's $11.6B acquisition of Bioverativ Inc..
First new drug from Bioverativ pipeline for rare autoimmune anemia. Part of Sanofi SA's $11.6B deal to acquire Bioverativ Inc..
Next-gen once-weekly Factor VIII driving 63% hemophilia A franchise growth. Part of Sanofi SA's $11.6B deal to acquire Bioverativ Inc..
~$2B writedown from Hemlibra but ALTUVIIIO reversed trajectory. Enjaymo divested to Recordati.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Bioverativ Inc. (this deal) | 2018 | $11.6B | 56 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2018 deals · Sanofi SA deals · Hematology deals